Insight Molecular Diagnostics Inc.

Healthcare

NASDAQ:IMDX · NASDAQ Capital Market

Market Cap $145.75M Beta 1.79 P/E (TTM) -4.0

$5.61 +3.31%

+$0.18 today

52W Low $2.33High $8.51

Vol 0.39M · Avg 0.37M

EPS (TTM)-$1.39

Medical - Diagnostics & Research

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+111.70%

Period High

$8.48

Period Low

$2.40

Latest

$5.61

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Cybin Inc.

CYBN

$413.02M

Prelude Therapeutics Incorporated

NASDAQ:PRLD

$352.45M

C4 Therapeutics, Inc.

NASDAQ:CCCC

$323.03M

Armata Pharmaceuticals, Inc.

AMEX:ARMP

$278.27M

OmniAb, Inc.

NASDAQ:OABI

$270.34M

Codexis, Inc.

NASDAQ:CDXS

$218.15M

Milestone Pharmaceuticals Inc.

NASDAQ:MIST

$109.08M

Invivyd, Inc.

NASDAQ:IVVD

$102.20M

PepGen Inc.

NASDAQ:PEPG

$101.68M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

$64.96M

What is the latest IMDX filing?

The latest filing shown is 8-K dated May 13, 2026.

How many recent filings does IMDX have?

Intrinsic Alpha currently shows 20 recent filings for IMDX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.